{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:21:20Z","timestamp":1777879280189,"version":"3.51.4"},"reference-count":79,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bulcan.2026.02.014","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:34:12Z","timestamp":1775752452000},"page":"677-687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Toxicit\u00e9s cardiovasculaires des principales th\u00e9rapies cibl\u00e9es orales dans les tumeurs solides"],"prefix":"10.1016","volume":"113","author":[{"given":"Simon","family":"Nannini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9ment","family":"Droesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Moinard-Butot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bulcan.2026.02.014_bib0405","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.bulcan.2026.02.014_bib0410","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.3390\/curroncol31080332","article-title":"New oncologic drugs from 2008\u00a0to 2023\u00a0\u2014\u00a0differences in approval and access between the United States, Europe and Brazil","volume":"31","author":"Barreto","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.bulcan.2026.02.014_bib0415","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Sig Transduct Target Ther"},{"issue":"6","key":"10.1016\/j.bulcan.2026.02.014_bib0420","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkaa076","article-title":"Cardiovascular toxicity of targeted therapies for cancer: an overview of systematic reviews","volume":"4","author":"Van Leeuwen","year":"2020","journal-title":"JNCI Cancer Spectr"},{"issue":"2","key":"10.1016\/j.bulcan.2026.02.014_bib0425","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4103\/2229-3485.71852","article-title":"Phase IV of drug development","volume":"1","author":"Suvarna","year":"2010","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.bulcan.2026.02.014_bib0430","series-title":"2022 ESC Guidelines on cardio-oncology developed in collboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and theInternational Cardio-Oncology Society (IC-OS)","author":"L\u00f3pez-Fern\u00e1ndez","year":"2022"},{"key":"10.1016\/j.bulcan.2026.02.014_bib0435","doi-asserted-by":"crossref","unstructured":"Ole-Petter R. Hamnvik, Toni K. Choueiri, Alexander Turchin, Rana R. McKay et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway \u2013\u00a0Hamnvik \u2013\u00a02015\u00a0\u2013 Cancer\u00a0\u2013 Wiley Online Library.","DOI":"10.1002\/cncr.28972"},{"issue":"2","key":"10.1016\/j.bulcan.2026.02.014_bib0440","first-page":"366","article-title":"Cardiovascular toxicity induced by vascular endothelial growth factor inhibitors","volume":"13","author":"Mihalcea","year":"2023","journal-title":"Life (Basel)"},{"issue":"1","key":"10.1016\/j.bulcan.2026.02.014_bib0445","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12894-019-0481-5","article-title":"Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Urol"},{"issue":"2","key":"10.1016\/j.bulcan.2026.02.014_bib0450","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.critrevonc.2014.12.008","article-title":"Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"94","author":"Ghatalia","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.bulcan.2026.02.014_bib0455","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1161\/HYPERTENSIONAHA.117.08856","article-title":"Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition","volume":"70","author":"Touyz","year":"2017","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.bulcan.2026.02.014_bib0460","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/JCMA.0000000000001026","article-title":"Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: a systemic review and network meta-analysis","volume":"87","author":"Chen","year":"2024","journal-title":"J Chin Med Assoc"},{"issue":"2","key":"10.1016\/j.bulcan.2026.02.014_bib0465","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/bjc.2014.564","article-title":"QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"112","author":"Ghatalia","year":"2015","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2026.02.014_bib0470","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.3390\/jcm9051268","article-title":"Cardiovascular complications of systemic therapy in non-small-cell lung cancer","volume":"9","author":"Zaborowska-Szmit","year":"2020","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.bulcan.2026.02.014_bib0475","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/annonc\/mdr592","article-title":"Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials","volume":"23","author":"Petrelli","year":"2012","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2026.02.014_bib0480","doi-asserted-by":"crossref","first-page":"e007724","DOI":"10.1161\/JAHA.117.007724","article-title":"Incidence, diagnosis, and management of qt prolongation induced by cancer therapies: a systematic review","volume":"6","author":"Porta-S\u00e1nchez","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.bulcan.2026.02.014_bib0485","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/bjc.2015.82","article-title":"Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors","volume":"112","author":"Kloth","year":"2015","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2026.02.014_bib0490","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bulcan.2026.02.014_bib0495","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bulcan.2026.02.014_bib0500","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","article-title":"Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS)","volume":"1","author":"Anand","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.bulcan.2026.02.014_bib0505","doi-asserted-by":"crossref","first-page":"e082834","DOI":"10.1136\/bmj-2024-082834","article-title":"Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: systematic review and network meta-analysis","volume":"390","author":"Ma","year":"2025","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.bulcan.2026.02.014_bib0510","first-page":"100224","article-title":"Cardiac safety assessment of lazertinib: findings from patients with EGFR mutation-positive advanced NSCLC and preclinical studies","volume":"2","author":"Jang","year":"2021","journal-title":"JTO Clin Res Rep"},{"issue":"16","key":"10.1016\/j.bulcan.2026.02.014_bib0515","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2026.02.014_bib0520","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2\u00a0study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2026.02.014_bib0535","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3390\/ijms26020554","article-title":"Matters of the heart: cardiotoxicity related to target therapy in oncogene-addicted non-small cell lung cancer","volume":"26","author":"Torresan","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"21","key":"10.1016\/j.bulcan.2026.02.014_bib0525","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer |","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2026.02.014_bib0540","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.acvd.2020.03.014","article-title":"Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and\/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis","volume":"113","author":"Dolladille","year":"2020","journal-title":"Arch Cardiovasc Dis"},{"issue":"9","key":"10.1016\/j.bulcan.2026.02.014_bib0545","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3\u00a0trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.02.014_bib0550","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bulcan.2026.02.014_bib0555","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3\u00a0trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.bulcan.2026.02.014_bib0560","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2026.02.014_bib0565","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.01.096","article-title":"Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors","volume":"4","author":"Glen","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.02.014_bib0570","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41392-024-01893-2","article-title":"Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts","volume":"9","author":"Kolesnichenko","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"10.1016\/j.bulcan.2026.02.014_bib0575","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","volume":"30","author":"Mateo","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2026.02.014_bib0580","doi-asserted-by":"crossref","first-page":"101154","DOI":"10.1016\/j.esmoop.2023.101154","article-title":"Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis","volume":"8","author":"Palazzo","year":"2023","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.bulcan.2026.02.014_bib0585","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S1470-2045(14)70320-1","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3\u00a0trial and their association with pathological complete response","volume":"15","author":"de Azambuja","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2026.02.014_bib0590","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/s41416-020-0786-x","article-title":"Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and\/or trastuzumab treatment optimization trial","volume":"122","author":"Eiger","year":"2020","journal-title":"Br J Cancer"},{"issue":"26","key":"10.1016\/j.bulcan.2026.02.014_bib0595","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.bulcan.2026.02.014_bib0600","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jamaoncol.2016.0237","article-title":"Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial","volume":"2","author":"Awada","year":"2016","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2026.02.014_bib0605","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","article-title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3\u00a0trial","volume":"18","author":"Martin","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2026.02.014_bib0610","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2026.02.014_bib0615","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jaccao.2022.09.007","article-title":"Pharmacovigilance analysis of heart failure associated with anti-HER2\u00a0monotherapies and combination regimens for cancer","volume":"5","author":"Waliany","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"36","key":"10.1016\/j.bulcan.2026.02.014_bib0620","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016\u00a0ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.bulcan.2026.02.014_bib0625","doi-asserted-by":"crossref","first-page":"e029361","DOI":"10.1161\/JAHA.123.029361","article-title":"Adverse cardiovascular events associated with cyclin-dependent kinase 4\/6\u00a0inhibitors in patients with metastatic breast cancer","volume":"12","author":"Fradley","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.bulcan.2026.02.014_bib0630","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1586\/era.10.234","article-title":"Safety and efficacy of moderate-dose capecitabine as first-line therapy in metastatic breast cancer","volume":"11","author":"Cortes-Funes","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"10.1016\/j.bulcan.2026.02.014_bib0635","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2026.02.014_bib0640","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.annonc.2022.03.006","article-title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study","volume":"33","author":"Rugo","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.02.014_bib0645","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1002\/onco.13531","article-title":"Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2\u00a0and MONARCH 3","volume":"26","author":"Rugo","year":"2021","journal-title":"Oncologist"},{"issue":"17","key":"10.1016\/j.bulcan.2026.02.014_bib0650","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/cncr.34367","article-title":"Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer","volume":"128","author":"Watson","year":"2022","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2026.02.014_bib0655","doi-asserted-by":"crossref","first-page":"e749","DOI":"10.1002\/onco.13684","article-title":"Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: updated analysis with up to 5\u00a0years of follow-up","volume":"26","author":"Finn","year":"2021","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.bulcan.2026.02.014_bib0660","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1002\/jcb.26687","article-title":"The prognostic value of PI3K mutational status in breast cancer: a meta-analysis","volume":"119","author":"Sobhani","year":"2018","journal-title":"J Cell Biochem"},{"issue":"4","key":"10.1016\/j.bulcan.2026.02.014_bib0665","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.hjc.2018.01.013","article-title":"Everolimus as cancer therapy: Cardiotoxic or an unexpected antiatherogenic agent? A narrative review","volume":"59","author":"Karvelas","year":"2018","journal-title":"Hellenic J Cardiol"},{"issue":"6","key":"10.1016\/j.bulcan.2026.02.014_bib0670","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.bulcan.2026.02.014_bib0675","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.bulcan.2026.02.014_bib0680","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bulcan.2026.02.014_bib0685","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.bulcan.2026.02.014_bib0690","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.bulcan.2026.02.014_bib0695","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"issue":"10378","key":"10.1016\/j.bulcan.2026.02.014_bib0700","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3\u00a0trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.bulcan.2026.02.014_bib0705","doi-asserted-by":"crossref","first-page":"e2300030","DOI":"10.1200\/PO.23.00030","article-title":"Clinical and genomic features of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer","author":"Thummalapalli","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2026.02.014_bib0710","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.bulcan.2026.02.014_bib0715","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with advanced solid tumors harboring a KRASG12C mutation","volume":"41","author":"Yaeger","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2026.02.014_bib0720","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nrc3143","article-title":"Gastrointestinal stromal tumours: origin and molecular oncology","volume":"11","author":"Corless","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.bulcan.2026.02.014_bib0725","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/ijc.33119","article-title":"Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors","volume":"147","author":"Abu Rmilah","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bulcan.2026.02.014_bib0730","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkel\u00e4","year":"2006","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.bulcan.2026.02.014_bib0735","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS)","volume":"12","author":"Cirmi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.bulcan.2026.02.014_bib0740","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3\u00a0trial","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2026.02.014_bib0745","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/annonc\/mdz394.087","volume":"30","author":"von Mehren","year":"2019","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.bulcan.2026.02.014_bib0750","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.2217\/fon-2022-0226","article-title":"Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval","volume":"18","author":"Goggin","year":"2022","journal-title":"Future Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2026.02.014_bib0755","doi-asserted-by":"crossref","first-page":"e639","DOI":"10.1002\/onco.13674","article-title":"Avapritinib in patients with advanced gastrointestinal stromal tumors following at least three prior lines of therapy","volume":"26","author":"George","year":"2021","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.bulcan.2026.02.014_bib0760","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1\u00a0mutation: the phase 3\u00a0randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2026.02.014_bib0765","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2026.02.014_bib0770","first-page":"100332","article-title":"Long-term efficacy and safety of entrectinib in ROS1\u00a0fusion-positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin Res Rep"},{"issue":"10","key":"10.1016\/j.bulcan.2026.02.014_bib0775","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"issue":"Supplement_1","key":"10.1016\/j.bulcan.2026.02.014_bib0780","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehae666.2693","article-title":"External validation of the HFA-ICOS risk stratification tool for prediction of cardiovascular complications after cancer treatment","volume":"45","author":"Gynnild","year":"2024","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.bulcan.2026.02.014_bib0785","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1684\/bdc.2014.1887","article-title":"Prise en charge des troubles m\u00e9taboliques observ\u00e9s avec \u00e9v\u00e9rolimus chez les patients atteints de tumeurs neuroendocrines bien diff\u00e9renci\u00e9es non r\u00e9s\u00e9cables\u00a0: propositions d\u2019experts","volume":"101","author":"Lombard-Bohas","year":"2014","journal-title":"Bull Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2026.02.014_bib0790","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3390\/cancers16020350","article-title":"Exploring the spectrum of VEGF inhibitors\u2019 toxicities from systemic to intra-vitreal usage in medical practice","volume":"16","author":"Santorsola","year":"2024","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.bulcan.2026.02.014_bib0795","doi-asserted-by":"crossref","first-page":"e1034","DOI":"10.1634\/theoncologist.2018-0773","article-title":"Prevention, monitoring, and management of cardiac dysfunction in patients with metastatic breast cancer","volume":"24","author":"Curigliano","year":"2019","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.bulcan.2026.02.014_bib0800","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","article-title":"Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events","volume":"12","author":"Touyz","year":"2018","journal-title":"J Am Soc Hypertens"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126001827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126001827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:39:31Z","timestamp":1777592371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126001827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0007455126001827"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.02.014","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicit\u00e9s cardiovasculaires des principales th\u00e9rapies cibl\u00e9es orales dans les tumeurs solides","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}